ArticleAnnals of medicine and surgery (2012)2025
Bioengineered urethral grafts for strictures: a perspective on advancements, functional restoration, and affordability.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urethral stricture is a chronic urological condition that remains challenging to manage due to the limitations of traditional treatments like dilation and urethroplasty, which are prone to recurrence and complications. Tissue-engineered urethral grafts have emerged as a promising alternative, offering durable, functional restoration with reduced donor site morbidity. Innovations in scaffold fabrication, especially 3D bioprinting and hydrogel-based bio-inks, have led to the creation of structurally and biologically compatible constructs that can regenerate native urothelial layers. However, high costs, technical complexity, and limited commercial viability have restricted their widespread clinical use. Future directions should prioritize cost-reduction strategies, scalable biomanufacturing, and head-to-head trials with current treatment standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.